Open AccessFirst line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age
Author(s) -
Angelica Petrillo,
Annalisa Pappalardo,
F Calabrese,
Giuseppe Tirino,
Luca Pompella,
Jole Ventriglia,
Maria Maddalena Laterza,
Marianna Caterino,
Vincenzo Sforza,
Vega Iranzo,
M. Biglietto,
Michele Orditura,
Fortunato Ciardiello,
Giovanni Conzo,
Carlo Molino,
Ferdinando De Vita
Publication year - 2019
Publication title -
journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.084
H-Index - 39
eISSN - 2219-679X
pISSN - 2078-6891
DOI - 10.21037/jgo.2019.06.02
Subject(s) - medicine , gemcitabine , neutropenia , anemia , population , pancreatic cancer , adverse effect , univariate analysis , performance status , paclitaxel , oncology , surgery , gastroenterology , toxicity , cancer , multivariate analysis , environmental health
Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel plus gemcitabine in geriatric population. Our study aims to show whether this schedule can be feasible in the elderly as first-line treatment for mPC.